<DOC>
	<DOC>NCT00564187</DOC>
	<brief_summary>Primary: - To evaluate the efficacy of two regimens of irbesartan in patients responding but not normalized at 6 weeks of treatment (schema N°1: maintenance 150 mg/day, schema n°2: 300 mg/day for 6 more weeks) Secondary: - To evaluate the percentage of patients with DBP &lt; 90 mmHg at 6 and 12 weeks - To evaluate the percentage of patients with SBP &lt; 140 mmHg at 6 and 12 weeks - To evaluate rate of adverse events during the study</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of the Dosage Adjustment of Aprovel® (Irbesartan) in Hypertensive Outpatients in Current Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Mild to Moderate hypertension (90mmHg&lt;DBP&lt;110mmHg and 140mmHg&lt;SBP&lt;180mmHg) Or new diagnosed hypertension (after 2 visits within 1 month), never treated before and responding to required conditions for a treatment with irbesartan, after an adapted but insufficient diet Or a patient having already been treated with a nonsatisfying antihypertensive treatment stopped since at least 2 weeks before the inclusion A minimum exam labs as required by WHOISH within the month before the inclusion Severe Arterial Hypertension (PAS &gt; than or = to 180 mm Hg or PAD &gt; than or = to 110 mmHg) Isolated Systolic Hypertension Secondary Hypertension Bilateral renal arterial stenosis or renal arterial stenosis Non surgically sterilised woman or non postmenopausal woman Confirmed sodium depletion Irbesartan hypersensitivity The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>